Overview

Safety &Efficacy of CF101 to Subjects With Uveitis

Status:
Withdrawn
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.
Phase:
Phase 2
Details
Lead Sponsor:
Can-Fite BioPharma